This report was first published by Endpoints News. To see the original version, click here
Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness.
The deal appears to be Bayer’s first pharma M&A move since Bill Anderson joined as CEO in mid-2023. He initiated a multi-year reorg, with the conglomerate currently grappling with thousands of lawsuits related to Monsanto.
您已阅读17%（471字），剩余83%（2303字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。